Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook
Capricor Therapeutics, Inc. has just turned into one of the wildest biotech stories of 2025.
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now
Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met both its primary and key secondary endpoints.GlobeNewswire
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025
Polyrizon Ltd has suddenly jumped from obscure micro‑cap to headline mover. On Tuesday, December 2, 2025, the Israeli biotech’s shares spiked roughly 130% in a single session after the company announced a key manufacturing upscaling milestone for its PL‑14 nasal allergy blocker platform. The stock closed at about $7.33 on Tuesday—up from $3.16 the prior session—with intraday highs above $8 and trading volume near 150 million shares. Pre‑market quotes on December 3 show the stock around $6, still dramatically higher than earlier in the week. StockAnalysis+1
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?
ImmunityBio, Inc. has jumped back onto traders’ and long‑term investors’ radar after a powerful late‑November rally in its share price, driven by blockbuster third‑quarter numbers for its cancer drug Anktiva and a wave of bullish commentary across financial media.
HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025
Hong Kong Exchanges & Clearing Limited traded slightly higher on Thursday, as investors digested a packed calendar of derivatives expiries, fresh sustainable‑finance headlines and the imminent launch of Hang Seng Biotech Index futures.
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom
Shares of Sarepta Therapeutics head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks tied to its gene therapy Elevidys.
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025
Telomir Pharmaceuticals shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors.
Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)
Shuttle Pharmaceuticals surged over 25% in after‑hours and pre‑market trading on November 21, 2025 after an S‑1 filing, recent private placement and Nasdaq compliance update. Here’s what’s driving SHPH stock today.
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025
InMed Pharmaceuticals Inc. is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name.
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025
Moderna secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028.
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025
Psyence Biomedical Ltd. is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading.
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025
NEW YORK, November 19, 2025 – Shares of Nuvation Bio Inc. exploded higher on Wednesday after B. Riley Securities initiated coverage with a bullish rating and a $12 price target, adding fresh fuel to a rally driven by the successful launch of the company’s lung cancer drug IBTROZI™ and a blockbuster third quarter. Investing.com+2Parameter+2
Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025
Shares of Can-Fite BioPharma Ltd. jumped on Tuesday after the company reported a striking 9‑year overall survival with a complete response in an advanced liver cancer patient treated with its investigational drug Namodenoson, and confirmed that a pivotal Phase III trial in hepatocellular carcinoma is now enrolling patients in multiple regions. GlobeNewswire+1
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025
Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks+1
Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025
On November 17, 2025, Annovis Bio, Inc. released new Phase 3 data in early Parkinson’s disease showing that its lead drug candidate buntanetap halted cognitive decline and improved key Alzheimer’s-related biomarkers in a significant subset of patients.Annovis Bio+1 The update triggered a sharp rally in ANVS stock and put fresh attention on the company’s multi-disease neurodegeneration strategy.
Applied Therapeutics (APLT) Stock Explodes on Heavy Volume as FDA Scrutiny and Cash Concerns Collide – November 17, 2025
Applied Therapeutics Inc. is back on traders’ radar today, with its penny stock surging on enormous volume despite intense regulatory uncertainty and a stretched balance sheet.
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025
Pfizer’s acquisition of Metsera, Inc. is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race.
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025
As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks
Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update
As of this afternoon on November 17, 2025, all company‑specific news about Autonomix Medical, Inc. centers on the same core development: new quality‑of‑life data from its pancreatic cancer PoC 1 study and the stock’s reaction to it.
TechStock² Updates
